Day one

2:00

Registration and Networking

MaRS Auditorium

30 min

Participate in 1:1 roulette style conversations

Hopin

30 min

2:30

Welcome to MaRS Impact Health

MaRS Auditorium and Hopin

5 min

What to expect at the conference this week.

What to expect at the conference this week.

2:35

Building a national biotech and life sciences ecosystem

MaRS Auditorium and Hopin

45 min

“You’ve got to think about building the racetrack and the facility of the racetrack, rather than...

“You’ve got to think about building the racetrack and the facility of the racetrack, rather than betting on individual horses.”
— Andrew Casey, President and CEO, BIOTECanada

 

It’s a common refrain: Canada is great at research, but we need to get better at commercializing our discoveries and anchoring them here. The last two years have been promising, so have we finally bridged the gap between discovery and commercialization in life sciences? What else is needed to address the investment, infrastructure and talent necessary to support a flourishing biotech industry in Canada? This panel will take an in-depth look at current efforts to build Canada’s biotech ecosystem, which includes nurturing ventures, raising capital, boosting manufacturing capacity and attracting talent.

3:15

Decentralizing biotech

MaRS Auditorium and Hopin

35 min

The traditional, centralized model of building biotech ventures has been gradually changing and may now be...

The traditional, centralized model of building biotech ventures has been gradually changing and may now be at an inflection point. Centralized funding, teams and tools are giving way to a more distributed model. This in turn has unlocked the ability for new founders to play by their own rules. How will this model work? Is it sustainable? Will virtual labs, cloud computing, DAOs, community funding and new models of collaboration change the way we commercialize science in the future? And will it be for the better? Hear from founders on the bleeding edge of this exciting space for insight on what might be next.

3:50

Out of the lab, into the patient: Canada’s commercial opportunity in cell and gene therapy manufacturing

MaRS Auditorium and Hopin

35 min

Canada’s cell and gene manufacturing industry is at an inflection point. Companies are transitioning from drug...

Canada’s cell and gene manufacturing industry is at an inflection point. Companies are transitioning from drug discovery into producing therapies for clinical trials. Looming on the horizon is the need for full-scale commercial manufacturing. But how much of that production will happen in Canada?

4:25

Break

4:40

Philanthropy and health innovation

MaRS Auditorium and Hopin

35 min

Foundations and donors across North America are finding new ways to catalyze health innovation. New funding...

Foundations and donors across North America are finding new ways to catalyze health innovation. New funding models, like venture philanthropy, aim to bridge the chasms between revolutionary research and the commercialization of lifesaving therapies and equipment. What new approaches can inspire people to give across the health innovation journey?

Day two

9:00

Registration and networking

MaRS Auditorium

60 min

Participate in 1:1 roulette style conversations

Hopin

60 min

9:45

Welcome, introductions and what to expect at MaRS Impact Health

9:50

Fireside chat with Pieter Cullis and Katalin Karikó: From basic research to world-changing therapies

MaRS Auditorium and Hopin

45 min

In April 2022, Katalin Karikó, senior vice president of BioNTech in Germany, was named one of...

In April 2022, Katalin Karikó, senior vice president of BioNTech in Germany, was named one of this year’s recipients of the Canada Gairdner International Award, one of the top global prizes in biomedicine. She was recognized alongside Pieter Cullis, the University of British Columbia scientist whose development of nanomedicines provided the delivery mechanism for COVID-19 vaccines.

 

This discussion, moderated by Janet Rossant, Gairdner Foundation president and scientific director, will explore how the two scientists produced one of the most consequential and widely used medical interventions in a generation: messenger RNA vaccines against COVID-19.

10:35

Tackling international markets: How Canadian ventures can address health challenges globally

MaRS Auditorium and Hopin

25 min

This session will feature several initiatives that support high potential health ventures that are ready to...

This session will feature several initiatives that support high potential health ventures that are ready to tackle global markets. Hear from entrepreneurs who are growing across the United States and in international markets through a blend of tailored connections to financing, innovation partners and export markets, funding programs, workshops, mentorship and networking.

11:00

Venture Showcase 1: Digital Health

MaRS Auditorium and Hopin

35 min

This session features pitches from six leading startups in digital health, followed by a Q&A with...

This session features pitches from six leading startups in digital health, followed by a Q&A with a panel of venture capitalists and industry thought leaders. Participants will have the chance to request 1-on-1 meetings with the presenting companies.

12:35

Lunch

1:00

Tackling misinformation and building trust in science

MaRS Auditorium and Hopin

30 min

During the pandemic, we saw firsthand how misinformation and distrust in science has a direct impact...

During the pandemic, we saw firsthand how misinformation and distrust in science has a direct impact on human health. False content amplified by social media makes it challenging for health officials and the public to navigate health information and make informed decisions. This discussion will explore the impact of misinformation and strategies for building trust in science and medicine.

1:30

Investor Roundtable

MaRS Auditorium and Hopin

40 min

Some of Canada’s top investors discuss major driving factors, challenges and prospects that will define the...

Some of Canada’s top investors discuss major driving factors, challenges and prospects that will define the growth of the health innovation sector in the coming years.

2:10

Heartbeat-tracking: Collaborating with big tech to drive better patient outcomes

MaRS Auditorium and Hopin

30 min

Dr. Heather Ross, a UHN expert in cardiology, talks about how physiologic signs from Apple devices...

Dr. Heather Ross, a UHN expert in cardiology, talks about how physiologic signs from Apple devices can help manage disease and prevent poor clinical outcomes.

2:40

Break

2:55

Venture Showcase 2: Medical Devices

MaRS Auditorium and Hopin

40 min

This session features pitches from six leading startups in medical devices, followed by a Q&A with...

This session features pitches from six leading startups in medical devices, followed by a Q&A with a panel of venture capitalists and industry thought leaders. Participants will have the chance to request 1-on-1 meetings with the presenting companies.

4:35

Bootstrap to billions: The Baylis Medical story

MaRS Auditorium and Hopin

25 min

Kris Shah, co-founder and president of Baylis Medical, describes how a bootstrapped Canadian health innovator landed...

Kris Shah, co-founder and president of Baylis Medical, describes how a bootstrapped Canadian health innovator landed a U.S.$1.75-billion sale to Boston Scientific. Kris shares how he scaled Baylis from two employees to a workforce of 1,000 and offers his take on how Canada can improve innovation success in the medical device space.

Day three

9:00

Participate in 1:1 roulette style conversations

Hopin

60 min

10:00

Welcome to Day 3

MaRS Auditorium and Hopin

5 min

10:05

Invention to market: Open science and commercialization

MaRS Auditorium and Hopin

30 min

What are the best new models for bringing life science innovation to the market? Can commercialization...

What are the best new models for bringing life science innovation to the market? Can commercialization and open science coexist? This discussion will try to square the seeming tension and essential partnership between intellectual property and open science in drug discovery.

10:40

Fireside chat with Nick Glover: Winning through (clinical) trials and errors

MaRS Auditorium and Hopin

20 min

11:00

A.I. and biotech

MaRS Auditorium and Hopin

35 min

A.I./M.L. innovations now affect almost every aspect of our lives. As the digital merges with the...

A.I./M.L. innovations now affect almost every aspect of our lives. As the digital merges with the biological, many new opportunities will emerge in our ability to discover, deploy and market new therapeutics. Meet several A.I.-based ventures — Cyclica, BenchSci, ODAIA and deepCDR — changing our perspectives on pharmaceuticals as they move from bench to bedside.

11:35

Medicine in the Metaverse

MaRS Auditorium and Hopin

40 min

The metaverse (or at least what it will become) has triggered the invention of a number...

The metaverse (or at least what it will become) has triggered the invention of a number of new medical devices and processes. And while critics have raised concerns about metaverse privacy and overhype, these healthcare products have real transformational substance. This panel features several ventures and clinicians using cutting-edge technologies to enhance care.

12:05

Lunch

12:35

Venture Pitch 3: Biotech

MaRS Auditorium and Hopin

35 min

This session features pitches from six leading startups in biotechnology, followed by a Q&A with a...

This session features pitches from six leading startups in biotechnology, followed by a Q&A with a panel of venture capitalists and industry thought leaders. Participants will have the chance to request 1-on-1 meetings with the presenting companies.

2:10

The power minority in biotech

MaRS Auditorium and Hopin

30 min

A discussion on gender equity in the biotech and life science industry, as well as the...

A discussion on gender equity in the biotech and life science industry, as well as the importance of prioritizing inclusive innovation in order to boost the commercialization of breakthrough science in Canada and tackle ongoing gaps in women’s healthcare.

2:45

Closing Remarks

Get your ticket before prices increase

Register now